Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Sponsor: Children's Hospital of Philadelphia
Summary
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.
Official title: Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)
Key Details
Gender
All
Age Range
1 Year - 21 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-12-29
Completion Date
2027-09
Last Updated
2025-12-04
Healthy Volunteers
No
Interventions
18F-Fluciclovine
18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
Locations (1)
The Children s Hospital of Philadelphia
Philadelphia, Pennsylvania, United States